ArticlePeerJ2019
Identification of a five-miRNA signature predicting survival in cutaneous melanoma cancer patients.
Article in PeerJ, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Circulating miRNAs as biomarkers for the diagnosis in patients with melanoma: systematic review and meta-analysis.Frontiers in genetics · 2024Pooled it
- Multiple roles of MicroRNAs in melanoma: biomarkers for diagnosis, prognosis, and treatment prediction.Frontiers in immunology · 2026Review
- Clinicopathological implications of miR-3127 in melanoma.Journal of pathology and translational medicine · 2025Article
- Non-coding RNA profiling in BRAFScientific data · 2025Article
- The Role of Non-coding RNAs in Tumorigenesis, Diagnosis/Prognosis, and Therapeutic Strategies for Cutaneous Melanoma.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Critical Considerations for Investigating MicroRNAs during Tumorigenesis: A Case Study in Conceptual and Contextual Nuances of miR-211-5p in Melanoma.Epigenomes · 2023Review
- MicroRNA as a Diagnostic Tool, Therapeutic Target and Potential Biomarker in Cutaneous Malignant Melanoma Detection-Narrative Review.International journal of molecular sciences · 2023Review
- Article
- Apprising Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma-Persistent Updating.Journal of personalized medicine · 2022Review
- Revisiting miRNA Association with Melanoma Recurrence and Metastasis from a Machine Learning Point of View.International journal of molecular sciences · 2022Review
- Identification of a five-miRNA signature as a novel potential prognostic biomarker in patients with nasopharyngeal carcinoma.Hereditas · 2022Article
- Hsa-let-7c-5p, hsa-miR-130b-3p, and hsa-miR-142-3p as Novel miRNA Biomarkers for Melanoma Progression.Genetics research · 2022Article
- Machine Learning Analysis of Immune Cells for Diagnosis and Prognosis of Cutaneous Melanoma.Journal of oncology · 2022Article
- MicroRNA-633 enhances melanoma cell proliferation and migration by suppressing KAI1.Oncology letters · 2021Article
- Investigation of molecular regulation mechanism under the pathophysiology of subarachnoid hemorrhage.Open life sciences · 2021Article
- Identification of Key miRNAs in the Treatment of Dabrafenib-Resistant Melanoma.BioMed research international · 2021Article
- Evaluation of FGFR1 as a diagnostic biomarker for ovarian cancer using TCGA and GEO datasets.PeerJ · 2021Article
- The Association of Residential Altitude on the Molecular Profile and Survival of Melanoma: Results of an Interreg Study.Cancers · 2020Article
- Current and Future Trends in Molecular Biomarkers for Diagnostic, Prognostic, and Predictive Purposes in Non-Melanoma Skin Cancer.Journal of clinical medicine · 2020Review
- Development and Validation of an Immune-Related Gene Pair Signature in Skin Cutaneous Melanoma.Clinical, cosmetic and investigational dermatology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous melanoma (CM) is the deadliest form of skin cancer. Numerous studies have revealed that microRNAs (miRNAs) are expressed abnormally in melanoma tissues. Our work aimed to assess multiple miRNAs using bioinformatic analysis in order to predict the prognoses of cutaneous melanoma patients.
methodsThe microarray dataset GSE35579 was downloaded from the Gene Expression Omnibus (GEO) database to detect the differential expression of miRNAs (DEMs), including 41 melanoma (primary and metastatic) tissues and 11 benign nevi. Clinical information and miRNA sequencing data of cutaneous melanoma tissues were downloaded from the Cancer Genome Atlas database (TCGA) to assess the prognostic values of DEMs. Additionally, the target genes of DEMs were anticipated using miRanda, miRmap, TargetScan, and PicTar. Finally, functional analysis was performed using selected target genes on the Annotation, Visualization and Integrated Discovery (DAVID) website.
resultsAfter performing bioinformatic analysis, a total of 185 DEMs were identified: 80 upregulated miRNAs and 105 downregulated miRNAs. A five-miRNA (miR-25, miR-204, miR-211, miR-510, miR-513c) signature was discovered to be a potential significant prognostic biomarker of cutaneous melanoma when using the Kaplan-Meier survival method (
conclusionThe identified five-miRNA signature may serve as a prognostic biomarker, or as a potential therapeutic target, in cutaneous melanoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.